To the more than two billion euros invested in pharmaceuticals, they add new investment
The pharmaceutical giant Sandoz plans to build new production facilities for active substances used in biosimilar medicines in Ljubljana, Slovenia. The investment is valued at approximately 300 million dollars and is expected to start operations in 2029. This expansion aims to strengthen Sandoz's production capabilities and support both clinical and commercial manufacturing across Europe. The project is part of the company’s strategy to achieve the Bio100 goal, which focuses on long-term opportunities in the field of biosimilars. Sandoz has a strong presence in Slovenia, including significant investments in Lendava.
Sandoz plans to establish a new production facility for biosimilar medicines in Ljubljana, valued at approximately 258 million euros. The facility will enable both clinical and commercial manufacturing and is scheduled to be operational by 2029. The investment is part of Sandoz’s strategy to expand its production capabilities for biosimilars within Europe. The new center will be located near an existing research and development hub for biosimilars, which opened earlier this summer on Verovška Street in Ljubljana. This marks the first major expansion in a series of initiatives aimed at establishing a comprehensive chain of operations, from development to manufacturing, within Slovenia. The project is expected to strengthen Sandoz's position in the biosimilar market and enhance its flexibility and responsiveness to market demands. According to Sandoz, the investment reflects confidence in long-term growth opportunities in the biosimilar sector and supports the company’s ambition to achieve the Bio100 goal. This target aims to capture significant long-term opportunities in the field of biosimilars. The facility will contribute to expanding Sandoz’s foundational production network for biosimilars based in Europe, covering technologies of varying scales. Chief Executive Officer Richard Saynor emphasized that the investment aligns with the company’s vision for sustainable growth and value creation. He noted that the new center will reinforce Sandoz’s ability to adapt to evolving market conditions and meet future challenges effectively. Armin Metzger, head of development, production, and supply for biosimilars at Sandoz, stated that the investment will further solidify the company’s foundation for future growth and increase control over production capacities. The facility will also improve flexibility and efficiency in manufacturing processes. The project represents a significant step forward for Sandoz in Slovenia, where the company has made substantial investments, including in Lendava. With the new center, Sandoz continues to expand its presence in the region while reinforcing its global leadership in the biosimilars industry.
Go to the primary sources (1)
The official sources this coverage is built on. Read them directly to bypass framing.
Švicarski farmacevtski velikan Sandoz je načrtoval gradnjo novih proizvodnih zmogljivosti za učinkovine podobnih bioloških zdravil v Ljubljani, vrednih 258 milijonov evrov. Novi center bo omogočal klinično in komercialno proizvodnjo ter se vzpostavil leta 2029. Naložba je del cilja Bio100, s katerim namerava Sandoz povečati svoje možnosti na področju podobnih bioloških zdravil. Center bo postavljen ob obstoječem razvojnem centru za podobna biološka zdravila v Ljubljani, kar bo omogočilo vzpostavitev celostne verige od razvoja do proizvodnje.
Bias read (Center): Čeprav je tematika povezana z gospodarstvom in investicijami, ki imajo možno politično vpliv, artikel ne uporablja zelo enstranskega okvirja ali izbičkanega sloga. Predstavlja informacijo o naložbi in njenem vplivu na gospodarstvo brez izraznega političnega stališča. Vse podatke in izjave so predstv
Why factuality (85): The article accurately reports that Sandoz plans to build a new production facility in Ljubljana for biosimilar drugs valued at €258 million, scheduled for completion by 2029. It includes direct quotes from Sandoz officials and aligns closely with the cross-source consensus, though it does not speci
Why objectivity (88): The tone remains largely neutral and factual, presenting information as reported by Sandoz without overt bias. Some promotional language is present, such as 'visokotehnološki center,' but this is typical of industry reporting. Overall, the article maintains balance and avoids strong subjective comme
The pharmaceutical giant Sandoz plans to build new production facilities for active substances used in biosimilar medicines in Ljubljana, Slovenia. The investment is valued at approximately 300 million dollars and is expected to start operations in 2029. This expansion aims to strengthen Sandoz's production capabilities and support both clinical and commercial manufacturing across Europe. The project is part of the company’s strategy to achieve the Bio100 goal, which focuses on long-term opportunities in the field of biosimilars. Sandoz has a strong presence in Slovenia, including significant investments in Lendava.
Bias read (Center): The article presents information about a major corporate investment in Slovenia without overtly favoring any political ideology. It provides factual details about Sandoz's plans, economic implications, and strategic goals without taking a clear ideological stance. While the topic involves national经济
Why factuality (80): This article also reports the planned investment in Ljubljana for biosimilar drug production, citing an approximate value of $300 million (equivalent to around €270 million). While slightly different from the first article’s figure, it aligns with the general consensus. The timeline and purpose of t
Why objectivity (85): The article presents the information objectively, using standard journalistic language. There is some mild promotional phrasing, such as 'močno prisotna v Sloveniji,' but no clear bias or emotional language. The framing is balanced, focusing on the economic implications rather than taking a stance o
How each side covered it
The same event, grouped by the political lean of the outlets covering it.
progressive
center
conservative
★
How each side covered it
Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.
Slovenia
